Irbesartan Tablet
Product Images NDC 71335-0071

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 71335-0071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350071)

Label for Irbesartan 300 mg tablet by Bryant Ranch Prepack. The label lists the product as a white oval tablet with identifier HH;331, compares it to Avapro 300 mg tablets from Zhejiang Huahai Pharma Co Ltd, and shows an NDC of 71335-0071. Storage instructions specify room temperature 20°-25°C (68°-77°F), with a note to take medication with or without food. The label also includes a lot number, barcode, and RX only indication.*

FDA Label Image

Structure (Spl Image1 Structure)

Chemical structure of Irbesartan, the active ingredient depicted by a detailed molecular diagram including rings and chemical groups characteristic of its composition.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A graph titled 'Placebo-subtracted reduction in trough SeSBP; integrated analysis,' plotting the relationship between Irbesartan dose (mg/day) on the x-axis and mmHg values on the y-axis. The graph shows scattered data points and a curve indicating the dose-response effect of Irbesartan tablets administered orally.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A scatter plot graph with a fitted curve showing the relationship between oral Irbesartan dose (mg/day) on the x-axis and placebo-subtracted reduction in trough SeDBP (mmHg) on the y-axis. Data points are scattered, with the curve indicating increasing blood pressure reduction with higher doses, leveling off at higher doses.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A line graph showing cumulative event rates (%) over months of follow-up for three groups: Irbesartan, Amlodipine, and Placebo. The graph compares treatment effects with relative risks (RR) and p-values listed for Irbesartan vs. Placebo and Irbesartan vs. Amlodipine, indicating statistical analysis of event rates over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.